Rheumatology
Partner With Us
Advertisement

Lupus & Connective Tissue Disorders

thumb description

November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

thumb description

November 20, 2024

CPPD Disease: More Common Than Previously Thought

In a paradigm shift for treating acute CPPD crystal arthritis, the 2023 COLCHICORT trial showed prednisone matched colchicine's efficacy with better tolerability in older patients, challenging long-held treatment assumptions.

Conexiant

thumb description

November 20, 2024

EBV: The Virus Behind Multiple Autoimmune Diseases

EBV infects >95% of adults globally, yet only triggers autoimmunity in some - researchers identified several key mechanisms, including autoimmune-promoting EBV strains and genetic variants, that may explain why certain individuals develop diseases like lupus, MS, and rheumatoid arthritis.

Conexiant

Daily News

Stay up to date with the latest clinical headlines.

thumb description

November 13, 2024

Systemic Sclerosis Lung Disease: Timing Matters Less

Although interstitial lung disease typically develops early in systemic sclerosis, a study of 969 patients revealed that ILD presenting after 7 years of disease showed identical progression rates and severity patterns as early-onset cases, challenging traditional monitoring assumptions.

Conexiant

thumb description

November 11, 2024

Late-Onset Interstitial Lung Disease Risk in Systemic Sclerosis

A recent study found that nearly half of systemic sclerosis patients with late-onset interstitial lung disease experience disease progression within four years. Key risk factors for late-onset ILD were identified, and surveillance is recommended, although optimal monitoring methods have yet to be established.

Conexiant